Allergan shares could rise 15%-20%, Barron's says Shares of Allergan could rise 15%-20% as the company's pipeline of products comes into investor focus over the next year, Barron's said over the weekend in its The Trader column. The stock could see greater returns should Allergan prevail over the FDA regarding generic Restasis, the paper added. Reference Link
News For AGN From The Last 14 Days
Check below for free stories on AGN the last two weeks.